Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Dec 26, 2024

BUY
$13.58 - $17.36 $820,951 - $1.05 Million
60,453 New
60,453 $950,000
Q1 2024

May 10, 2024

SELL
$13.58 - $17.36 $362,518 - $463,425
-26,695 Reduced 30.63%
60,453 $950,000
Q4 2023

Dec 26, 2024

BUY
$10.11 - $16.54 $881,066 - $1.44 Million
87,148 New
87,148 $1.41 Million
Q4 2023

Feb 12, 2024

BUY
$10.11 - $16.54 $44,959 - $73,553
4,447 Added 5.38%
87,148 $1.41 Million
Q3 2023

Nov 14, 2023

BUY
$12.46 - $15.48 $29,243 - $36,331
2,347 Added 2.92%
82,701 $1.05 Million
Q2 2023

Aug 11, 2023

BUY
$13.28 - $15.96 $158,151 - $190,067
11,909 Added 17.4%
80,354 $1.13 Million
Q1 2023

May 18, 2023

BUY
$14.26 - $22.1 $951,641 - $1.47 Million
66,735 Added 3902.63%
68,445 $1.06 Million
Q1 2023

May 11, 2023

SELL
$14.26 - $22.1 $1.03 Million - $1.6 Million
-72,302 Reduced 97.69%
1,710 $26,000
Q4 2022

Feb 13, 2023

SELL
$14.85 - $19.04 $79,551 - $101,997
-5,357 Reduced 6.75%
74,012 $1.21 Million
Q3 2022

Nov 14, 2022

BUY
$12.38 - $20.23 $459,570 - $750,978
37,122 Added 87.87%
79,369 $1.47 Million
Q2 2022

Aug 11, 2022

SELL
$9.11 - $13.98 $2.93 Million - $4.49 Million
-321,234 Reduced 88.38%
42,247 $556,000
Q1 2022

May 11, 2022

BUY
$6.87 - $11.11 $1.65 Million - $2.66 Million
239,535 Added 193.26%
363,481 $3.37 Million
Q4 2021

Feb 10, 2022

BUY
$7.7 - $37.13 $748,825 - $3.61 Million
97,250 Added 364.29%
123,946 $1.21 Million
Q3 2021

Nov 12, 2021

BUY
$26.46 - $37.15 $706,376 - $991,756
26,696 New
26,696 $907,000

Others Institutions Holding DCPH

About Deciphera Pharmaceuticals, Inc.


  • Ticker DCPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,822,100
  • Description
  • Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...
More about DCPH
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.